Rumored Pfizer (PFE) Deal to Buy Cellectis (ALCLS) for $1.64 Billion Could Lock in CRISPR and CAR T Tech
ASCO15: Eyebrows Are Raised As Puma Biotech (PBYI) Turns Away Investors, Analyst for ASCO Event
Here's What Juno Therapeutics (JUNO) Really Thinks About Local Rival Adaptive Biotech
Rapamune, Pfizer (PFE)'s Branding-Troubled Drug, Gets FDA Approval for Rare Lung Disease
Celldex (CLDX)'s Brain Cancer Drug Rintega Will Take Center Stage at ASCO
Bay Area's Heron (HRTX) Rockets as Nausea Drug Meets Goals in Phase III Study
ASCO15 EXCLUSIVE: Onxeo Will Run Phase III Trial For Oral Mucositis By End of 2015, CEO Tells BioSpace (DHX)
EXCLUSIVE: Biotech's Bull Run Perfect for M&A, Onxeo CEO Tells BioSpace (DHX)
The Most Exciting Companies in Biotech
Novartis AG (NVS) to Eliminate Up to 110 U.S. Jobs Through Voluntary Retirement Offering
Pfizer (PFE) Will Lay Off 750 Workers at Pearl River Site in 2017, Inks New Land Deal
Gilead (GILD) Will Hire Up to 170 Scientists in $100 Million Edmonton Expansion
Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow
Gilead (GILD)’s Hep B Trial Failure Will Inspire M&A Activity, Say Analysts
Teva (TEVA) Buys Stake in Mylan (MYL), As Takeover Attempt Turns Nasty
BioPharm Executive: Here's How The Drug Industry Will Finally Hang Itself
Pronutria Bags $39M for Research, Possible Staff Expansion and Recruits Two Ex-Vertex (VRTX) Execs
Investors Wait With Bated Breath for ImmunoGen (IMGN)'s Ovarian Cancer Drug ASCO News
See All News >
//-->